A Multicenter, Comparative, Open Label, Prospective Observational Study on Discontinuation of Medication Due to Gastrointestinal Adverse Effects for the Patients Being Treated for Osteoarthritis With Anti-inflammatory Analgesic Drug
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2018
Price : $35 *
At a glance
- Drugs GCSB 5 (Primary) ; Celecoxib; Nonsteroidal anti-inflammatories
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors GC Pharma
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 16 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 16 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.